Navigation Links
first in Medical Technology

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development fo...

World's First Cardiac Adult Stem Cell Patient Receives Infusion

Trial taking place in Louisville, KY LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- Michael (Mike) Jones has become the world's first recipient of adult cardiac stem cells to treat congestive heart failure. Jones' infusion on July 17 marks the world's first phase-one...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

MILWAUKEE, RICHMOND, Calif., ST LOUIS, PALO ALTO, Calif., and PARIS, July 23 /PRNewswire-FirstCall/ -- Scientists from The Medical College of Wisconsin in Milwaukee, Sangamo Biosciences, Inc., (Nasdaq: SGMO ), Sigma-Aldrich Corporation (Nasdaq: SIAL ), Open Monoclonal Technology...

Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today during a lease signing event that it has become the first tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, a development that sh...

GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas

LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first and only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key fin...

McCaughey Urges Use of First NYS Hospital Infection Report

NEW YORK, June 30 /PRNewswire-USNewswire/ -- Betsy McCaughey of the Committee to Reduce Infection Deaths (RID) urges families to make use of hospital infection rates made available by the NYS Department of Health today. "Now patients can learn which hospitals in their area have the lowest infecti...

West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial

Collaboration will test remote wireless monitoring to prevent hospital readmissions for heart failure SAN DIEGO, June 24 /PRNewswire-USNewswire/ -- The West Wireless Health Institute (WWHI), one of the world's first medical research organizations dedicated to advancing health and well-being t...

Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Florida's First Three-Year Neuroscience Research Doctorate Program SARASOTA, Fla., June 18 /PRNewswire/ -- Sarasota's Roskamp Institute (Roskamp) today announced the first enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laborator...

Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product

SALT LAKE CITY, June 17 /PRNewswire/ -- Great Basin Scientific, Inc., a privately held life sciences company developing novel, point-of-care molecular diagnostic solutions, today announced it has closed $3.6 million in bridge funding to support the company through 2009 and the launch of its first ...

HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study

Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the f...

Scottsdale Facility to Be First in U.S. to Showcase True REST Technology

Research Shows Numerous Benefits Including Stress Reduction, Pain Relief and Improved Sleep Patterns SCOTTSDALE, Ariz., June 16 /PRNewswire/ -- According to the American Medical Association, stress is a factor in more than 75 percent of illness today. The World Health Organization cites stres...

WORLD'S First Robotic Assisted Kidney Transplant Performed at Saint Barnabas Medical Center

LIVINGSTON, N.J., June 4 /PRNewswire/ -- Transplant surgeon, Stuart R. Geffner, M.D., Director of Kidney and Pancreas Transplant Surgery, Saint Barnabas Health Care System Renal and Pancreas Transplant Division, is the first in the world to use the Intuitive Surgical's da Vinci(TM) Surgical System...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic BASEL, Switzerland, June 1 /PRNewswire/ -- Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. - The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem C...

Creighton Medical Laboratories First to Offer New Cancer Test

OMAHA, Neb., May 15 /PRNewswire/ -- Creighton Medical Laboratories, based at Creighton University School of Medicine in Omaha, announced today that it has become the first clinical laboratory worldwide to offer a new and more effective testing method for cancer. The method, called SNP arra...

Spherix Reports First Quarter 2009 Earnings

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the...

Tris Pharma Announces Acceptance of Its First Two NDAs

- First ever 24 hour oral liquid sustained release formulation submitted to the FDA - Validates OralXR(TM) technology platform - eliminates the need to swallow pills by providing sustained release in liquids, chewable tablets, and films - Upon approval will provide both liquid and tablet...

Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus

Real-time PCR test validated using clinical specimens confirmed positive for Influenza A H1N1 Swine-origin flu virus MADISON, N.J., May 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and service...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) ...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

EMERYVILLE, Calif., May 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) today announced first quarter highlights and financial results for the three months ended March 31, 2009. Company Highlights Bionovo presented data on a preclinical anti-cancer drug candi...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

Conference Call Scheduled for Today - Thursday, May 7, 2009 at 5:30 p.m. Eastern Time MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial results for the quarter ended March 31, 2009, and provided an update on its prod...

BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009

BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the first quarter ended March 31, 2009, and ...

Transcept Pharmaceuticals to Report First Quarter 2009 Results

RICHMOND, Calif., May 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

Largest Study to Date Will Evaluate SilverHawk Plaque Excision System for Treatment of Lower Extremity Peripheral Arterial Disease PLYMOUTH, Minn., April 30 /PRNewswire/ -- ev3 Inc. (Nasdaq: EVVV ) today announced that the first patients were recently enrolled in the DEFINITIVE LE post-...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its...

Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin

Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical...

Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses

Test of prototype 3D display exceeds performance expectations. LIVONIA, Mich., April 20 /PRNewswire/ -- On Friday, March 20, 2009, in Taylor, Michigan, three Oakwood Heritage Hospital surgeons and their medical support team assembled to perform a series of surgical procedures on a cadaver to ...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceut...

PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)

- Company Reports Significant Uptake of PlasmaBlade by U.S. Surgeons Since Product Launch - PALO ALTO, Calif., April 7 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, announced today several mil...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first clinical trial application (CTA) in Eur...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV)....

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - ...

Nation's Laboratory Response Network Marks First Decade of Protecting Public Health

SILVER SPRING, Md., March 30 /PRNewswire-USNewswire/ -- The Laboratory Response Network (LRN), the national laboratory system charged with protecting the public in health emergencies, will mark its first decade at its national meeting in Orlando, Florida, April 1-3, 2009. Founded in 1999 by t...

Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development

BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

KING OF PRUSSIA, Pa., March 11 /PRNewswire/ -- CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP(TM) is the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven ye...

Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient

ANN ARBOR, Mich., March 9 /PRNewswire/ -- Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ Columbia University Medical Center recently became the second U.S. center, and first in the Northeast, to implant the DuraHeart(TM) Left-Ventricular Assist System as part of the DuraHe...

IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile

Patient Has Mobility Immediately and Makes Rapid Recovery after Procedure Utilizing IlluminOss(TM) Photodynamic Bone Stabilization System SANTIAGO, Chile, Feb. 24 /PRNewswire/ -- IlluminOss Medical today announced that one of the leading surgeons in Chile, Dr. Sebastian von Unger, has perform...
Other Tags
(Date:7/10/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... June 26, 2014 that its Board of Directors had ... or approximately $40 million in total.  The Board established ... payment date of July 24, 2014.  The Company was ... ex-dividend date for this special cash dividend.  An ex-dividend ...
(Date:7/10/2014)... BELL, Pa. , July 2, 2014  Unisys Corporation,s ... Netherlands , Unisys Nederland N.V., today announced that it ... to deliver, implement and manage a new Basic Provision Biometrics ... Unisys won the contract with a solution ... identity management software. The term of the contract is up ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a ... that CEO Mr. Gino Pereira was interviewed on ... in Tampa Florida . Mr. Pereira discusses ... Cedric Harris and how the Wocket™ aims to ... Cedric Harris tells Gino he ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- In people with sex ... similar to that seen in drug addicts as they ... clear differences in brain activity between patients who have ... those of drug addicts," study author Dr. Valerie Voon, ... a university news release. Voon,s research involved 19 ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
(Date:7/11/2014)... Ohio (PRWEB) July 11, 2014 As ... 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of ... blood sugar, abdominal issues and even death from the ... , According to the Times report , a ... in 2013 reported by patients was almost 14% of ...
(Date:7/11/2014)... News) -- Delaying surgery to repair damage to the anterior ... of the knee -- could increase a young athlete,s risk ... records of 130 patients, aged 8 to 16, who had ... than six weeks after their injury, 37 had surgery six ... than three months after their injury. The youngsters who ...
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
Breaking Medicine News(10 mins):Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
Other Contents